As with every hormone, research shows melatonin levels typically decline with age. Melatonin levels begin to decline around age 30. Then, there is a significant decrease in melatonin levels after age 40, which accelerates as patients approach age 60.
Growing scientific data shows that melatonin supplementation can promote both improved sleep onset and maintenance in this patient population.† However, until recently, the delivery of exogenous melatonin in the body has not been fully optimized for this purpose.
The clinical and real-world data behind REMfresh® is unprecedented for any melatonin product offered in the United States. REMfresh’s 7-hour innovation is supported by three lanes of clinical proof. First is the breakthrough 7-hour Pharmacokinetic Data (REMAKT), second is the depth of real-world patient-reported data found in REMVAL and REMSS, and finally the REMSU24 study, one of the few large-scale adverse event reports on melatonin that has been peer reviewed, which points to REMfresh’s outstanding safety profile.Reference: Point 4
REMfresh contains 2 mg of melatonin in a continuous-release and absorption formulation
Fast onset and sleep maintenance:†
Quick release and absorption of melatonin within the first hour after dosing, to obtain a faster onset of action†
A flat-topped (plateau) release profile—similar to the body’s own melatonin release profile
Exceeds 1000 pcg/ml plasma levels for up to 7 hours to help induce and maintain a full night of sleep including, deep restorative sleep†